Published in J Hepatol on February 19, 2011
Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC) | NCT00464919
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol (2012) 2.01
Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma. Liver Cancer (2012) 1.02
Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study. Invest Radiol (2014) 0.99
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol (2013) 0.97
Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer (2013) 0.95
Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation. Pharmaceutics (2012) 0.94
¹⁸F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study. PLoS One (2013) 0.90
DCE-MRI of the liver: effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibility. J Magn Reson Imaging (2013) 0.88
Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging (2012) 0.86
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol (2015) 0.86
DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. World J Gastroenterol (2014) 0.85
Quantitative characterization of hepatocellular carcinoma and metastatic liver tumor by CT perfusion. Cancer Imaging (2013) 0.83
Multiparametric MR Imaging in Abdominal Malignancies. Magn Reson Imaging Clin N Am (2016) 0.83
Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer (2015) 0.82
Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol (2013) 0.81
Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol (2015) 0.81
SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma. Oncotarget (2015) 0.80
Functional MRI and CT biomarkers in oncology. Eur J Nucl Med Mol Imaging (2015) 0.79
Reproducibility of Dynamic Contrast-Enhanced MRI in Renal Cell Carcinoma: A Prospective Analysis on Intra- and Interobserver and Scan-Rescan Performance of Pharmacokinetic Parameters. Medicine (Baltimore) (2015) 0.79
Imaging of HCC-Current State of the Art. Diagnostics (Basel) (2015) 0.79
Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol (2015) 0.78
Assessment of blood flow in hepatocellular carcinoma: correlations of computed tomography perfusion imaging and circulating angiogenic factors. Int J Mol Sci (2013) 0.76
Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib. Clin Mol Hepatol (2014) 0.76
Prognostication and response assessment in liver and pancreatic tumors: The new imaging. World J Gastroenterol (2015) 0.76
New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol (2014) 0.76
DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model-initial experience. MAGMA (2015) 0.75
Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian J Radiol Imaging (2015) 0.75
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial. Cancer Res Treat (2016) 0.75
Arterial blood supply of hepatocellular carcinoma is associated with efficacy of sorafenib therapy. Ann Transl Med (2015) 0.75
Contrast agents in dynamic contrast-enhanced magnetic resonance imaging. Oncotarget (2017) 0.75
Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model. Eur Radiol (2016) 0.75
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. Eur Radiol (2016) 0.75
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology (2014) 3.92
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol (2013) 3.26
Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter pylori-independent gastric MALT lymphoma. Genes Chromosomes Cancer (2011) 3.25
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology (2008) 2.55
Adaptive momentum-based motion detection approach and its application on handoff in wireless networks. Sensors (Basel) (2009) 2.17
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology (2003) 2.15
Clinical studies with curcumin. Adv Exp Med Biol (2007) 2.14
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol (2011) 2.12
Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology (2011) 2.07
Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood (2012) 2.03
Serum bicarbonate as a marker to predict mortality in toxic epidermal necrolysis. J Intensive Care Med (2011) 1.98
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol (2008) 1.93
Late initiation of renal replacement therapy is associated with worse outcomes in acute kidney injury after major abdominal surgery. Crit Care (2009) 1.80
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther (2011) 1.77
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study. Oncology (2013) 1.70
Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant (2009) 1.67
Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials (2009) 1.67
A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. J Pediatr (2010) 1.60
Preoperative proteinuria predicts adverse renal outcomes after coronary artery bypass grafting. J Am Soc Nephrol (2010) 1.58
Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology (2009) 1.58
Blood perfusion of vertebral lesions evaluated with gadolinium-enhanced dynamic MRI: in comparison with compression fracture and metastasis. J Magn Reson Imaging (2002) 1.57
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials. Oncology (2011) 1.52
Standardized mortality ratio of inpatient suicide in a general hospital. J Formos Med Assoc (2011) 1.52
Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev (2005) 1.51
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res (2010) 1.50
Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett (2008) 1.50
Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology (2011) 1.48
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer (2010) 1.48
Acute-on-chronic kidney injury at hospital discharge is associated with long-term dialysis and mortality. Kidney Int (2011) 1.47
Survival-weighted health profile for long-term survivors of acute myelogenous leukemia. Qual Life Res (2003) 1.46
Risk factors of early redialysis after weaning from postoperative acute renal replacement therapy. Intensive Care Med (2007) 1.45
The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database. Pharmacoepidemiol Drug Saf (2008) 1.44
Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma: a preliminary result. Liver Int (2007) 1.44
RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology (2008) 1.43
Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever. Crit Care Med (2011) 1.41
Effectiveness of education programs about oral antibiotic suspensions in pediatric outpatient services. Pediatr Neonatol (2012) 1.41
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide. Hepatol Int (2014) 1.40
Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res (2008) 1.40
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res (2011) 1.39
OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma. Cancer Res (2008) 1.36
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst (2005) 1.35
Identification and characterization of a novel gene Saf transcribed from the opposite strand of Fas. Hum Mol Genet (2005) 1.31
FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res (2008) 1.31
Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res (2008) 1.30
Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Res (2008) 1.30
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol (2010) 1.24
Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. Am J Kidney Dis (2010) 1.24
Kidney function decline after a non-dialysis-requiring acute kidney injury is associated with higher long-term mortality in critically ill survivors. Crit Care (2012) 1.24
Early renal replacement therapy in patients with postoperative acute liver failure associated with acute renal failure: effect on postoperative outcomes. J Am Coll Surg (2007) 1.24
Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappaB activation by protein phosphatase 4-mediated NF-kappaB p65 Thr dephosphorylation. J Biol Chem (2004) 1.24
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology (2007) 1.21
Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev (2009) 1.20
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol Cancer Ther (2011) 1.19
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res (2005) 1.19
The 90-day mortality and the subsequent renal recovery in critically ill surgical patients requiring acute renal replacement therapy. Am J Surg (2009) 1.17
Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol (2012) 1.16
Percutaneous computed tomography-guided coaxial core biopsy for small pulmonary lesions with ground-glass attenuation. J Thorac Oncol (2012) 1.16
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head Neck (2005) 1.16
Tuberculous infection of the wrist: MRI features. AJR Am J Roentgenol (2004) 1.16
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem (2009) 1.15
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer (2002) 1.15
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas (2008) 1.14
Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res (2006) 1.14
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. Cancer Res (2013) 1.14
Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res (2007) 1.14
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer (2010) 1.13
Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc (2013) 1.12
Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology (2003) 1.12
ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res (2008) 1.11
Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13. Qual Life Res (2004) 1.11
Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol (2006) 1.10
Rhabdomyolysis: magnetic resonance imaging and computed tomography findings. J Comput Assist Tomogr (2007) 1.09
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma. Hum Pathol (2009) 1.08
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol (2010) 1.08
Bacterial pyomyositis: MRI and clinical correlation. Magn Reson Imaging (2004) 1.07
Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res (2010) 1.07